On Tuesday, Teva Pharmaceutical stock got a positive adjustment to its Relative Strength (RS) Rating, from 68 to 74.
This exclusive rating from Investor's Business Daily measures price performance with a 1 (worst) to 99 (best) score. The score shows how a stock's price performance over the trailing 52 weeks compares to all the other stocks in our database.
Over 100 years of market history shows that the best stocks typically have an 80 or better RS Rating as they launch their biggest price moves. See if Teva Pharmaceutical stock can continue to show renewed price strength and hit that benchmark.
When To Sell Stocks To Lock In Profits And Minimize Losses
Is Teva Pharmaceutical Stock A Buy?
Teva Pharmaceutical stock has been trading below its 50- and 200-day moving averages the last few months. While now is not an ideal time to invest, this stock belongs on your watch list. Wait and see if the stock is able to offer and clear an appropriate buy point.
The generic drug company posted negative growth for both the top and bottom lines last quarter.
Teva Pharmaceutical stock earns the No. 8 rank among its peers in the Medical-Generic Drugs industry group. ANI Pharmaceuticals, Collegium Pharmaceutical and Haleon ADR are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
